TJ-M2010-2 is a small molecule inhibitor of MyD88 homodimerization, interacts with MyD88 TIR domain.
TJ-M2010-2 partially inhibited MyD88 homodimerization at 10 μM and completely inhibited MyD88 homodimerization at 40 μM.
TJ-M2010-2 alone or with CD154 antagonist mAb MR1 improves survival rate, prevents renal dysfunction and attenuates pathologic damage after IRI.
TJ-M2010-2 alone or with MR1 decreases IRI-induced apoptosis, inhibits DC maturation in vitro and decreases DC-mediated T-cell proliferation.
TJ-M2010-2 attenuates renal fibrosis after IRI and prevents EMT in vitro.
TJ-M2010-2 down-regulates the TLR/MyD88 signaling pathway.
